{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HEPATOCELLULAR+CARCINOMA&page=3",
    "query": {
      "condition": "HEPATOCELLULAR CARCINOMA",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1038,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HEPATOCELLULAR+CARCINOMA&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HEPATOCELLULAR+CARCINOMA&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T23:02:25.664Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01489410",
      "title": "Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Drug-Eluting Beads (DEB) with Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Lipiodol Ethanol Mixture",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-10",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-31",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489410"
    },
    {
      "nct_id": "NCT07224568",
      "title": "Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor (Excluding CNS)",
        "Hepatocellular Carcinoma",
        "Liver Cell Carcinoma",
        "Liposarcoma",
        "Yolk Sac Tumor",
        "Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "SC-CAR.GPC3xIL15.21 CAR T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seattle Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2026-04-01",
      "completion_date": "2045-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224568"
    },
    {
      "nct_id": "NCT00087191",
      "title": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Adult Primary Liver Cancer",
        "Carcinoma of the Appendix",
        "Fallopian Tube Cancer",
        "Gastrointestinal Stromal Tumor",
        "Localized Extrahepatic Bile Duct Cancer",
        "Localized Gallbladder Cancer",
        "Localized Gastrointestinal Carcinoid Tumor",
        "Localized Resectable Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Ovarian Sarcoma",
        "Ovarian Stromal Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Colon Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Recurrent Gastric Cancer",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pancreatic Cancer",
        "Recurrent Rectal Cancer",
        "Recurrent Small Intestine Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Gastrointestinal Carcinoid Tumor",
        "Small Intestine Adenocarcinoma",
        "Small Intestine Leiomyosarcoma",
        "Small Intestine Lymphoma",
        "Stage 0 Non-small Cell Lung Cancer",
        "Stage I Adult Soft Tissue Sarcoma",
        "Stage I Colon Cancer",
        "Stage I Gastric Cancer",
        "Stage I Non-small Cell Lung Cancer",
        "Stage I Ovarian Epithelial Cancer",
        "Stage I Ovarian Germ Cell Tumor",
        "Stage I Pancreatic Cancer",
        "Stage I Rectal Cancer",
        "Stage I Uterine Sarcoma",
        "Stage II Adult Soft Tissue Sarcoma",
        "Stage II Colon Cancer",
        "Stage II Gastric Cancer",
        "Stage II Non-small Cell Lung Cancer",
        "Stage II Ovarian Epithelial Cancer",
        "Stage II Ovarian Germ Cell Tumor",
        "Stage II Pancreatic Cancer",
        "Stage II Rectal Cancer",
        "Stage II Uterine Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Colon Cancer",
        "Stage III Gastric Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Ovarian Germ Cell Tumor",
        "Stage III Pancreatic Cancer",
        "Stage III Rectal Cancer",
        "Stage III Uterine Sarcoma",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Colon Cancer",
        "Stage IV Gastric Cancer",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Pancreatic Cancer",
        "Stage IV Rectal Cancer",
        "Stage IV Uterine Sarcoma",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "EF5",
          "type": "DRUG"
        },
        {
          "name": "motexafin lutetium",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-16",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087191"
    },
    {
      "nct_id": "NCT00370513",
      "title": "A Phase I Study of Pazopanib in Adult Patients With Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2006-12-06",
      "completion_date": "2009-04-08",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00370513"
    },
    {
      "nct_id": "NCT02029690",
      "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pleural Mesothelioma Malignant Advanced",
        "Peritoneal Mesothelioma Malignant Advanced",
        "Non-squamous Non-small Cell Lung Carcinoma",
        "Uveal Melanoma",
        "Hepatocellular Carcinoma",
        "Glioma",
        "Sarcomatoid Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2014-04-23",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029690"
    },
    {
      "nct_id": "NCT00101036",
      "title": "Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Recurrent Gallbladder Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer",
        "Unresectable Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2004-11",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101036"
    },
    {
      "nct_id": "NCT02432963",
      "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Bladder Carcinoma",
        "Colon Carcinoma",
        "Estrogen Receptor Negative",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "HER2/Neu Negative",
        "Melanoma",
        "Non-Small Cell Lung Carcinoma",
        "Pancreatic Carcinoma",
        "Progesterone Receptor Negative",
        "Rectal Carcinoma",
        "Renal Cell Carcinoma",
        "Soft Tissue Sarcoma",
        "Triple-Negative Breast Carcinoma",
        "TP53 Gene Mutation",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Modified Vaccinia Virus Ankara Vaccine Expressing p53",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-06-14",
      "completion_date": "2026-10-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432963"
    },
    {
      "nct_id": "NCT03517332",
      "title": "Circulating Tumor DNA Exposure in Peripheral Blood",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Adenocarcinoma",
        "Gastric Cancer",
        "Hepatocellular Carcinoma",
        "Non-small Cell Lung Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Ovarian Cancer",
        "Adrenocortical Cancer",
        "Breast Cancer",
        "Other Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Quantgene Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2015-01-01",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Centerville",
          "state": "Ohio"
        },
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03517332"
    },
    {
      "nct_id": "NCT04874519",
      "title": "Registry to Collect Health Information Related to Fibrolamellar Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fibrolamellar Cancer",
        "FLC",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-11-24",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04874519"
    },
    {
      "nct_id": "NCT01755767",
      "title": "Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tivantinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 383,
      "start_date": "2012-12-27",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-10-03T23:02:25.664Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01755767"
    }
  ]
}